The MedTech Intelligence Industry Survey is a primary research initiative designed to capture the perspectives of professionals working across the medical technology sector. The study is intended to examine the pressures, priorities, technology shifts, operational challenges, and strategic changes influencing MedTech organizations in 2026.
According to Deloitte, only 22% of life sciences leaders say they have successfully scaled AI, and just 9% report achieving significant returns. For materiovigilance, this highlights the growing gap between execution and team expectations. Within this gap, fragmented data and manual processes continue to slow response times and increase compliance risk, creating a disconnect between the promise of real-time safety monitoring and operational reality. How can organizations close this execution gap and evolve materiovigilance from a reactive compliance function into a proactive, data-driven discipline?
What 524B and QMSR actually require, in plain terms, including the post-market obligation that does not end at clearance? How both map to four kinds of exposure: cybersecurity, product liability, recall, and management liability. Where device makers are commonly unprepared against the new baseline, including the gap between cyber risk and product liability for software and devices.
A MedTech survey revealed that most sales teams are not using AI for strategic purposes, such as identifying opportunities, prioritizing accounts, or research. Instead, AI is mostly deployed to complete administrative tasks, such as drafting emails and summarizing meetings. Why is more needed?
Zimmer Biomet will hire 500 professionals over the next three years for its new Bengaluru technology centre, expanding its AI, software engineering, and R&D capabilities as India strengthens its position as a global healthcare innovation hub.
CMS’s proposed expansion of Medicare TAVR coverage to include select asymptomatic severe aortic stenosis patients and reduce access barriers for symptomatic patients could significantly increase TAVR adoption, creating a growth opportunity for Edwards Lifesciences through expanded eligibility, higher procedure volumes, and continued leadership in structural heart care.
Medtronic announced several regulatory milestones for its Hugo robotic-assisted surgery platform, including FDA submissions for general and gynecologic surgery indications and the LigaSure™ RAS instrument, alongside FDA clearance for its ProGrip™ Advanced hernia mesh. The developments expand the company’s robotic surgery portfolio and support its growth strategy in minimally invasive surgical care.
Medtronic reported robust fiscal 2026 results, fueled by strong growth in cardiovascular, medical surgical, and diabetes technologies, while advancing key product launches, regulatory milestones, and strategic acquisitions.
Boston Scientific will invest $138 million to build a 500,000-square-foot global medical device distribution facility in Plainfield, Indiana, creating up to 300 high-wage jobs and expanding the state’s growing life sciences sector.
The most recent AI thought leadership published on MedTechIntelligence.com.
